A Phase II Open-Labeled, Double-Arm Clinical Study of Dichloroacetate (DCA) [sodium dichloroacetate] in Malignant Gliomas and Glioblastome Multiforme (GBM) Patients.

Trial Profile

A Phase II Open-Labeled, Double-Arm Clinical Study of Dichloroacetate (DCA) [sodium dichloroacetate] in Malignant Gliomas and Glioblastome Multiforme (GBM) Patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2010

At a glance

  • Drugs Sodium dichloroacetate (Primary)
  • Indications Glioblastoma; Glioma
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 12 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Oct 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 24 Jun 2009 Planned end date changed from 1 Nov 2008 to 1 Dec 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top